Andrew H Galligan
CIK 1417976 · Chief Financial Officer · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.24M
Companies
3
Total Filings
57
Lifetime Open-Market Net
-$16.57M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OOMA | Director | 250,824 | $20.88 | $5.24M | -$940.2K | 17 | 2026-06-08 |
| Arcellx, Inc. (ACLX) Delisted | Director | 0 | $115.07 | $0 | $0 | 3 | 2026-04-28 |
| NEVRO CORP (NVRO) Delisted | Chief Financial Officer | 59,179 | $5.84 | $345.6K | -$15.63M | 31 | 2020-06-08 |
Recent Filings · Page 4 of 6
57 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-07 | OOMA | Grant (A) | +10,912 | $0 | EDGAR |
| 2018-05-16 | NEVRO CORP (NVRO) Delisted | Mixed | — | -$407.0K | EDGAR |
| 2018-03-05 | NEVRO CORP (NVRO) Delisted | Mixed | — | -$434.7K | EDGAR |
| 2017-11-16 | NEVRO CORP (NVRO) Delisted | Mixed | +13,000 | -$399.7K | EDGAR |
| 2017-11-13 | NEVRO CORP (NVRO) Delisted | Exer (M) | +4,000 | $5.8K | EDGAR |
| 2017-11-03 | NEVRO CORP (NVRO) Delisted | Tax (F) | −641 | -$57.0K | EDGAR |
| 2017-08-16 | NEVRO CORP (NVRO) Delisted | Mixed | — | -$548.1K | EDGAR |
| 2017-06-22 | OOMA | Grant (A) | +12,805 | $0 | EDGAR |
| 2017-05-16 | NEVRO CORP (NVRO) Delisted | Mixed | — | -$537.7K | EDGAR |
| 2017-05-11 | NEVRO CORP (NVRO) Delisted | Exer (M) | +5,000 | $7.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.